01 July 2021
The following documents have been updated and applicants to C19RM are requested to review them when preparing their funding request submissions.
The Global Fund has published two new documents outlining interim quality assurance requirements for the procurement of COVID-19 medical devices [ download in English | Español | Français ] and pharmaceuticals [ download in English | Español | Français ] .
All COVID-19 Medical Devices are to be consistent with current national or institutional standard treatment guidelines or with the World Health Organization (WHO) treatment guidelines or guidance or information notes released by the Global Fund. Additional requirements apply to certain higher risk products, as described in the guidance.
All pharmaceutical products procured with Global Fund resources are to be compliant with:
These COVID-19 Pharmaceutical Products cure or prevent COVID-19 and are exclusive of essential medicines used for the management of patients with suspected or confirmed COVID-19. Although no such products are yet eligible for procurement, the QA requirements are in place in anticipation.
The Guide to Global Fund Policies on Procurement and Supply Management of Health Products [ download in English | Español | Français ] has been updated, in particular to incorporate the two interim QA requirements described above.
Wambo.org is currently available to both Global Fund implementers using Global Fund resources and to governments and other eligible organizations using domestic or other donor funding that would like to secure products through the Pooled Procurement Mechanism and other procurement channels available through wambo.org.
Eligible buyers, regardless of funding source, have access to all products, services and functionalities in wambo.org, including framework agreements for HIV and malaria products, in addition to certain TB and COVID-19 products. For more information on wambo.org, please visit this page.